pharmaphorum.com

Share

pharmaphorum.com

 •  December 8

Kathy Talkington, Project Director from Pew Charitable Trusts, will discuss the “Shared Platform for Antibiotic Research and Knowledge” when she presents a keynote on “SPARKing” new antibiotic drug discovery at SMi’s 20th annual conference on Superbugs and Superdrugs next March in Central London. With a background in managing and developing...

pharmaphorum.com

 •  November 30

Antibody Drug Conjugates (ADCs) are treatments formed by the conjugation of monoclonal antibodies and cytotoxic agents. Although just two currently have FDA/EMC approval, Genentech’s Kadcyla® (ado-trastuzumab emtansine) and SeattleGenetics’ Adcetris® (brentuximab vedotin), there are now estimated to be 60 in the clinical trial stage of development...

pharmaphorum.com

 •  November 30

SMi reports: Andrew Hopkins, Chief Executive at Exscientia to discuss the role of Artificial Intelligence in small molecule drug discovery at SMi’s Drug Discovery conference in March 2018 The world’s leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline...

pharmaphorum.com

 •  November 9

The FDA has approved a new Merck & Co drug to prevent infections in patients who have had stem cell transplants. Cytomegalovirus (CMV) infection can cause major complications after stem cell transplants, and while there are already antiviral treatments available, they have shortcomings. Merck has therefore developed Prevymis (letermovir) to give...

pharmaphorum.com

 •  October 31

Biotech Apitope plans to float on the Brussels stock exchange to raise funds to develop a potential new MS drug. The Anglo-Belgian company specialises in producing peptides that are smaller and easier to manufacture than conventional antibody therapies. If successful, the fundraising will help it overcome last year’s setback when Merck KGaA walked...

pharmaphorum.com

 •  October 25

Microsoft is partnering with life sciences consulting firm Parexel to develop software capable of accelerating drug development. The collaboration will use Microsoft’s Azure cloud computing platform, onto which Parexel will move its Informatics software. Informatics’ core technology is Perceptive MyTrials which gives researchers single point access...

pharmaphorum.com

 •  October 20

Celgene has axed its gene silencing therapy in Crohn’s disease after an analysis of a phase 3 trial showed the drug was unlikely to produce results. The decision looks likely to end the development of mongersen, a drug that Celgene paid $710 million for. The company will not continue with the phase 3 REVOLVE trial, or begin its extension phase,...

pharmaphorum.com

 •  October 18

There’s much talk about patient-centric trials – collecting feedback and insight from patients and incorporating it into study designs in a quantifiable way is key to ensuring success, explains QuintilesIMS vice president of consulting services, Jean Paty. Pharma companies are increasingly talking about making trials ‘patient centric’, but matching...

pharmaphorum.com

 •  October 11

In recent decades there has been a dramatic increase in ocular imaging technologies—both for the anterior and posterior segments. This has been largely to the result of increased computer processing power, as applied to hardware control and data analysis. The technologies required to deliver agents specifically and effectively to the eye are...

pharmaphorum.com

 •  September 5

Using advanced technology and the skills of the data scientist for data source management from diverse sources can bring many benefits to the speed and quality of clinical trials, says Jim Streeter. It’s logical to think that expanding data sources in clinical trials can lead to more therapies, but does this additional data speed up or slow down a...